DPP4 and type 2 diabetes mellitus: These results indicate that the plasma concentration of trelagliptin even at 168 hours after 100 mg dosing is enough to sustain its pharmacodynamic effect, i.e., 70% inhibition of plasma DPP-4 activity, by weekly dosing of trelagliptin in T2DM patients.